Hypertension in mice lacking the CXCR3 chemokine receptor

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 4, 2009, Pages

  Hsu, Hsiang Hao ^a,d   Duning, Kerstin ^a   Meyer, Hans Henning ^a   Stölting, Miriam ^a   Weide, Thomas ^a   Kreusser, Stefanie ^a   Van Le, Truc ^a   Gerard, Craig ^c   Telgmann, Ralph ^b   Brand Herrmann, Stefan Martin ^b   Pavenstädt, Hermann ^a,e   Bek, Martin Johannes ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Department of Molecular Genetics of Cardiovascular Disease ^*  (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acetylcholine receptor; Angiotensin II type 1 receptor; CXCR3 knockout mice; EMSA; Transcription factors; Vascular contractility

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATROPINE; CHEMOKINE RECEPTOR CXCR3; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; EARLY GROWTH RESPONSE FACTOR 1; TRANSCRIPTION FACTOR SP 1; UNCLASSIFIED DRUG;

ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; HYPERTENSION; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESISTANCE BLOOD VESSEL; SMOOTH MUSCLE FIBER; STIMULATION; VASODILATATION; WILD TYPE;

EID: 65949109483     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90444.2008     Document Type: Article

References (55)

1. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 22: 147-184, 2001. (Pubitemid 32706335)
2. Bek MJ, Eisner GM, Felder RA, Jose PA. Dopamine receptors in hypertension. Mt Sinai J Med 68: 362-369, 2001.
3. +-ATPase activity in an immortalized human proximal tubule cell line. J Immunol 170: 931-940, 2003.
4. Bek MJ, Wang X, Asico LD, Jones JE, Zheng S, Li X, Eisner GM, Grandy DK, Carey RM, Soares-da-Silva P, Jose PA. Angiotensin II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice. Hypertension 47: 288-295, 2006. (Pubitemid 43192004)
5. Davis W Jr, Chen ZJ, Ile KE, Tew KD. Reciprocal regulation of expression of the human adenosine 5′-triphosphate binding cassette, sub-family A, transporter 2 (ABCA2) promoter by the early growth response-1 (EGR-1) and Sp-family transcription factors. Nucleic Acids Res 31: 1097-1107, 2003.
6. De Mey JG, Brutsaert DL. Mechanical properties of resting and active isolated coronary arteries. Circ Res 55: 1-9, 1984.
7. Decker EL, Skerka C, Zipfel PF. The early growth response protein (EGR-1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells. J Biol Chem 273: 26923-26930, 1998. (Pubitemid 28471713)
8. Duffy AA, Martin MM, Elton TS. Transcriptional regulation of the AT1 receptor gene in immortalized human trophoblast cells. Biochim Biophys Acta 1680: 158-170, 2004.
9. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 26: 219-233, 2006.
10. Garcia-Lopez MA, Sanchez-Madrid F, Rodriguez-Frade JM, Mellado M, Acevedo A, Garcia MI, Albar JP, Martinez C, Marazuela M. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest 81: 409-418, 2001. (Pubitemid 32245072)
11. Goldberg SH, van der MP, Hesselgesser J, Jaffer S, Kolson DL, Albright AV, Gonzalez-Scarano F, Lavi E. CXCR3 expression in human central nervous system diseases. Neuropathol Appl Neurobiol 27: 127-138, 2001. (Pubitemid 32591969)
12. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193: 975-980, 2001. (Pubitemid 32525870)
13. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 192: 1515-1520, 2000.
14. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, Gerszten RE. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113: 2301-2312, 2006. (Pubitemid 43947976)
15. Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, Ramachandran R, Wersinger SR, Soares-da-Silva P, Liu ZF, Grinberg A, Drago J, Young WS III, Westphal H, Jose PA, Sibley DR. Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. J Neurosci 22: 10801-10810, 2002. (Pubitemid 36005154)
16. 15a. Hsu HH, Hoffmann S, Endlich N, Velic A, Schwab A, Weide T, Schlatter E, Pavenstädt H. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med 86: 1379-1394, 2008.
17. Ishii M, Kurachi Y. Muscarinic acetylcholine receptors. Curr Pharm Des 12: 3573-3581, 2006. (Pubitemid 44509627)
18. 2+ exchanger type 1 in vascular smooth muscle. Nat Med 10: 1193-1199, 2004.
19. Jat PS, Noble MD, Ataliotis P, Tanaka Y, Yannoutsos N, Larsen L, Kioussis D. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc Natl Acad Sci USA 88: 5096-5100, 1991. (Pubitemid 21914690)
20. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, Fan J, Gao Y, Yin Z, Homer R, Gerard C, Noble PW. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest 114: 291-299, 2004. (Pubitemid 39071634)
21. Khurana S, Chacon I, Xie G, Yamada M, Wess J, Raufman JP, Kennedy RH. Vasodilatory effects of cholinergic agonists are greatly diminished in aorta from M3R-/- mice. Eur J Pharmacol 493: 127-132, 2004. (Pubitemid 38746941)
22. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34, 2000. (Pubitemid 30127593)
23. Koyano-Nakagawa N, Nishida J, Baldwin D, Arai K, Yokota T. Molecular cloning of a novel human cDNA encoding a zinc finger protein that binds to the interleukin-3 promoter. Mol Cell Biol 14: 5099-5107, 1994. (Pubitemid 24235937)
24. Kriwacki RW, Schultz SC, Steitz TA, Caradonna JP. Sequence-specific recognition of DNA by zinc-finger peptides derived from the transcription factor Sp1. Proc Natl Acad Sci USA 89: 9759-9763, 1992.
25. Kuznetsova T, Staessen JA, Brand E, Cwynar M, Stolarz K, Thijs L, Tikhonoff V, Wojciechowska W, Babeanu S, Brand-Herrmann SM, Casiglia E, Filipovsky J, Grodzicki T, Nikitin Y, Peleska J, Struijker-Boudier H, Bianchi G, Kawecka-Jaszcz K. Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension. J Hypertens 24: 235-242, 2006. (Pubitemid 43348228)
26. Li XX, Bek M, Asico LD, Yang Z, Grandy DK, Goldstein DS, Rubinstein M, Eisner GM, Jose PA. Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type 2 knockout mice. Hypertension 38: 303-308, 2001. (Pubitemid 34225656)
27. Lifton RP. Molecular genetics of human blood pressure variation. Science 272: 676-680, 1996.
28. Liu L, Callahan MK, Huang D, Ransohoff RM. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol 68: 149-181, 2005.
29. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315: 672-676, 1985.
30. Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, Lu B, Farber J, Luster AD, Kelley VR. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol 19: 1177-1189, 2008.
31. Menzaghi C, Paroni G, De BC, Soccio T, Marucci A, Bacci S, Trischitta V. The -318 C>G single-nucleotide polymorphism in GNAI2 gene promoter region impairs transcriptional activity through specific binding of Sp1 transcription factor and is associated with high blood pressure in Caucasians from Italy. J Am Soc Nephrol 17: S115-S119, 2006.
32. Mordelet E, Davies HA, Hillyer P, Romero IA, Male D. Chemokine transport across human vascular endothelial cells. Endothelium 14: 7-15, 2007. (Pubitemid 46978765)
33. Nakaya I, Wada T, Furuichi K, Sakai N, Kitagawa K, Yokoyama H, Ishida Y, Kondo T, Sugaya T, Kawachi H, Shimizu F, Narumi S, Haino M, Gerard C, Matsushima K, Kaneko S. Blockade of IP-10/CXCR3 promotes progressive renal fibrosis. Nephron Exp Nephrol 107: e12-e21, 2007. (Pubitemid 47355797)
34. Oberleithner H, Riethmuller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA 104: 16281-16286, 2007. (Pubitemid 350099397)
35. Panzer U, Steinmetz OM, Paust HJ, Meyer-Schwesinger C, Peters A, Turner JE, Zahner G, Heymann F, Kurts C, Hopfer H, Helmchen U, Haag F, Schneider A, Stahl RA. Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J Am Soc Nephrol 18: 2071-2084, 2007. (Pubitemid 47041073)
36. Panzer U, Steinmetz OM, Reinking RR, Meyer TN, Fehr S, Schneider A, Zahner G, Wolf G, Helmchen U, Schaerli P, Stahl RA, Thaiss F. Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury. J Am Soc Nephrol 17: 454-464, 2006.
37. Pickering G. Hypertension: definitions, natural histories, consequences. In: Hypertension, Pathophysiology, Diagnosis, and Management, edited by Laragh JH and Brenner BM. New York: Raven, 1995, p. 3-22.
38. Ragozzino D. CXC chemokine receptors in the central nervous system: role in cerebellar neuromodulation and development. J Neurovirol 8: 559-572, 2002. (Pubitemid 36104720)
39. Romagnani P, Beltrame C, Annunziato F, Lasagni L, Luconi M, Galli G, Cosmi L, Maggi E, Salvadori M, Pupilli C, Serio M. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol 10: 2518-2526, 1999.
40. Sarai A, Kono H. Protein-DNA recognition patterns and predictions. Annu Rev Biophys Biomol Struct 34: 379-398, 2005. (Pubitemid 40847730)
41. Sarris AH, Broxmeyer HE, Wirthmueller U, Karasavvas N, Cooper S, Lu L, Krueger J, Ravetch JV. Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J Exp Med 178: 1127-1132, 1993. (Pubitemid 23260454)
42. Segerer S, Cui Y, Eitner F, Goodpaster T, Hudkins KL, Mack M, Cartron JP, Colin Y, Schlondorff D, Alpers CE. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 37: 518-531, 2001. (Pubitemid 32195291)
43. Skerka C, Decker EL, Zipfel PF. A regulatory element in the human interleukin 2 gene promoter is a binding site for the zinc finger proteins Sp1 and EGR-1. J Biol Chem 270: 22500-22506, 1995.
44. Spieker LE, Flammer AJ, Luscher TF. The vascular endothelium in hypertension. Handb Exp Pharmacol 176: 249-283, 2006.
45. Srivastava S, Weitzmann MN, Kimble RB, Rizzo M, Zahner M, Milbrandt J, Ross FP, Pacifici R. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J Clin Invest 102: 1850-1859, 1998. (Pubitemid 28533832)
46. Steinmetz M, Potthast R, Sabrane K, Kuhn M. Diverging vasorelaxing effects of C-type natriuretic peptide in renal resistance arteries and aortas of GC-A-deficient mice. Regul Pept 119: 31-37, 2004. (Pubitemid 38482099)
47. Taub DD. Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev 7: 355-376, 1996.
48. Teramoto K, Negoro N, Kitamoto K, Iwai T, Iwao H, Okamura M, Miura K. Microarray analysis of glomerular gene expression in murine lupus nephritis. J Pharm Sci 106: 56-67, 2008.
49. Thottassery JV, Sun D, Zambetti GP, Troutman A, Sukhatme VP, Schuetz EG, Schuetz JD. Sp1 and egr-1 have opposing effects on the regulation of the rat Pgp2/mdr1b gene. J Biol Chem 274: 3199-3206, 1999. (Pubitemid 29075409)
50. Topham PS, Csizmadia V, Soler D, Hines D, Gerard CJ, Salant DJ, Hancock WW. Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest 104: 1549-1557, 1999. (Pubitemid 30002366)
51. van der MP, Goldberg SH, Fung KM, Sharer LR, Gonzalez-Scarano F, Lavi E. Expression pattern of CXCR3, CXCR4, and CCR3 chemokine receptors in the developing human brain. J Neuropathol Exp Neurol 60: 25-32, 2001. (Pubitemid 32097003)
52. van Wanrooij EJ, de Jager SC, van ET, de VP, Birch HL, Owen DA, Watson RJ, Biessen EA, Chapman GA, van Berkel TJ, Kuiper J. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 28: 251-257, 2008.
53. Zeng C, Yang Z, Asico LD, Jose PA. Regulation of blood pressure by D5 dopamine receptors. Cardiovasc Hematol Agents Med Chem 5: 241-248, 2007. (Pubitemid 47180855)
54. Zeng C, Yang Z, Wang Z, Jones J, Wang X, Altea J, Mangrum AJ, Hopfer U, Sibley DR, Eisner GM, Felder RA, Jose PA. Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells. Hypertension 45: 804-810, 2005. (Pubitemid 40418385)
55. Zhang X, Liu Y. Suppression of HGF receptor gene expression by oxidative stress is mediated through the interplay between Sp1 and Egr-1. Am J Physiol Renal Physiol 284: F1216-F1225, 2003. (Pubitemid 36578449)